Could the body’s cannabinoid system calm inflamed, injured lungs?
Modulation of Respiratory Diseases by the Endocannabinoid System: A Therapeutic Perspective.
AI Summary
Respiratory diseases such as asthma, pulmonary fibrosis, respiratory syncytial virus infection, and acute lung injury can involve damaging inflammation and disruption of the lung’s air–blood barrier. This review examines how the endocannabinoid system—a network of receptors, naturally produced signalling molecules, and metabolic enzymes—helps regulate lung inflammation and tissue integrity.
The authors describe potential treatment strategies that target this system, including receptor-specific compounds and drugs that slow the breakdown of endocannabinoids. However, the review emphasizes that endocannabinoid system activity can have different effects depending on the disease, so treatments would need to be highly selective. The findings do not establish that smoking or vaping cannabis treats respiratory disease; instead, they point toward future, medically designed cannabinoid-based therapies that still require clinical testing.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.